Examining the CONVOKE Clinical Trial
Panelists discuss the CONVOKE clinical trial, a 16-week study focused on patients with negative symptoms.
The trial incorporated patient input in app development, showing improvements in negative symptoms, depression, and cognitive function.
- Pure negative symptoms were the focus, excluding prominent positive symptoms.
- Severe cognitive impairment, suicidality, or substance abuse were excluded.
Patients with schizophrenia participated in designing the digital therapeutic application.
This approach ensured the tool addressed their lived experiences and symptom presentations.
The CONVOKE clinical trial represents a significant advancement in developing targeted treatments for patients with negative symptoms of schizophrenia.
Author's summary: The CONVOKE trial improves schizophrenia treatment.
More News
- Slideshow: Bethel comes together to celebrate Indigenous Peoples' Day
- DA outraged by brutal Mpumalanga farm attack
- 20 Things To Do in Grapevine for the Perfect Texas Getaway
- Ange Postecoglou is 'not the biggest mistake' at Nottingham Forest despite winless streak
- Popette: Pedro Pascal stays booked and busy
- How Computer-Aided Design Changed the World - CEOWORLD magazine
- Trial for Detroit woman found alive in body bag delayed
- Demon Slayer's Box Office Success Is Going to Be Trouble for Its Future
- Cognac Delamain Lot 62 / TV RES (Malternative Belgium)
- Are Twiggy Forrest’s green goals uneconomic or has China bounced him? - Switzer Daily